The TiP-HepC Evidence Base: An Online Review of the Evidence for HepC Screening and Treatment in Pregnancy

The TiP-HepC Evidence Base: An Online Review of the Evidence for HepC Screening and Treatment in Pregnancy

As part of the “Treatment In Pregnancy for Hepatitis C: TiP-HepC Registry”, a new searchable Evidence Base of peer-reviewed literature related to hepatitis C (HCV) screening and treatment in pregnancy is now available on the Coalition’s website.

Though direct-acting antiviral (DAA) medications have been proven to be effective and safe for non-pregnant persons, HCV treatment is not recommended for pregnant persons due to the lack of data on safety. HCV treatment during pregnancy could substantially increase treatment coverage and prevent mother-to-child transmission. The overall goal of the TiP-HepC project is to consolidate existing data and engage a community of practice among relevant stakeholders to prospectively inform appropriate decision-making for HCV treatment in pregnancy.

As a foundation to this project, the TiP-HepC Evidence Base consolidates the existing data related to HCV burden of disease among pregnant persons, HCV mother-to-child transmission, HCV testing in pregnancy, and HCV treatment options during pregnancy. This Evidence Base helps identify where there is information available to inform clinical care, program implementation, and future research.  

The systematic review was conducted in PubMed for articles published from January 1, 2013 - July 1, 2021 using search terms for “Hepatitis C virus” AND “pregnancy” AND “treatment” OR “direct-acting antivirals.”  Over 200 primary and secondary research articles were identified. Most of the primary research articles focused on:

  • Outcomes of HCV vertical transmission in infants
  • HCV screening results, epidemiology of HCV
  • Cost-effectiveness or policies for HCV testing

There were only a few studies related to maternal linkage to HCV treatment and limited data regarding the safety of DAA treatment in pregnancy. 

The web-based searchable database features the primary research articles and allows users to search the articles by intervention, type of study, and country. Explore the articles here: https://www.globalhep.org


For the next stage of the project, a clinical case registry will be launched to collect safety data on pregnant persons exposed to HCV DAAs and their infants. If you are interested in contributing data or collaborating on the TiP-HepC project, contact Dr. Neil Gupta at ngupta-consultant [at] taskforce.org ().  More information on TiP-HepC and how to contribute is available here. The TiP-HepC project is supported by the US Centers for Disease Control and Prevention.